Inactief instrument

Andere talen NuGenerex Immuno-Oncology, Inc.

Aandelen

NUGX

US67053X1028

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

NUGENEREX IMMUNO-ONCOLOGY, INC. : Changes in Control or Registrant, Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	10-04-23
NUGENEREX IMMUNO-ONCOLOGY, INC. : Other Events (form 8-K)	23-07-21
NUGENEREX IMMUNO ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	14-06-21
Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Third Quarter Ended April 30, 2021	14-06-21
NuGenerex Immuno-Oncology, Inc. has completed an IPO in the amount of $50.000004 million.	19-05-21
NUGENEREX IMMUNO-ONCOLOGY, INC. : Other Events (form 8-K)	27-04-21
NuGenerex Immuno-Oncology, Inc. Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission	12-04-21
NUGENEREX IMMUNO ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	12-03-21
Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Second Quarter Ended January 31, 2021	12-03-21
Nugenerex Immuno-Oncology, Inc. and Generex Biotechnology Corporation Signs an Extension for the Receipt of the USD 5,000,000.00 Upfront Licensing Fee Payment	17-12-20
NuGenerex to Seek Merger or Acquisition Opportunities	15-12-20
Generex Biotechnology Corporation and Nugenerex Immuno-Oncology Grants Licensing Rights to Bintai Healthcare Sdn Bhd	25-11-20
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand	23-11-20
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Distribution and Licensing Agreement with Bintai Healthcare SDN BHD	09-10-20
NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets	07-10-20
Bintai Healthcare Sdn Bhd Enters into A Distribution and Licensing Agreement with Generex Biotechnology Corporation and Its Majority Owned Subsidiary, Nugenerex Immuno-Oncology, Inc	06-10-20
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Agreement with Bintai Kinden Corporation of Malaysia for the Development and Commercialization of the II-Key-SARS-CoV-2 Coronavirus Vaccine	24-09-20
NuGenerex Immuno-Oncology, Inc. has filed an IPO in the amount of $1 million.	14-09-20
Bintai Kinden Corporation Berhad Announces Memorandum of Understanding with Nugenerex Immuno-Oncology on New Business Opportunity (COVID-19 Vaccine)	17-08-20
Nugenerex Immuno-Oncology Closes $50 Million Financing Facility	15-07-20

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen NuGenerex Immuno-Oncology, Inc.

Aandelen

NUGX

US67053X1028

Andere talen

Filters